Novel Vaccine Shows Broad Protection Against Fentanyl Analogs in Mouse Study

A study published in the *Journal of Medicinal Chemistry* reports that a newly engineered vaccine can elicit antibodies that recognize fentanyl and multiple illicit analogs—including carfentanil, acetyl-fentanyl, and furanylfentanyl—while ignoring standard medical opioids such as morphine, methadone, and oxycodone. The approach replaces the piperidine ring of fentanyl with a constrained scaffold, creating a hapten that preserves the spatial and electronic features common to the drug class.

Psypost

Female Swiss-Webster mice (n = 6 per group) received four intraperitoneal injections of either the modified vaccine, a conventional fentanyl-derived vaccine, or carrier protein alone (weeks 0, 2, 4, 8). Serum collected at weeks 3, 5, and 9 showed broad antibody binding to fentanyl analogs. In dose-response tests, unvaccinated mice displayed drug effects at ~150 µg kg?¹, whereas the modified-vaccine group required 1,400–1,800 µg kg?¹ for comparable responses. Respiratory monitoring revealed that control mice’s breathing fell to ~40 % of baseline within ten minutes of fentanyl exposure, while vaccinated mice maintained normal respiration for the full 45-minute observation. Brain fentanyl concentrations dropped from 61.9 nM in controls to 17.2 nM in vaccinated mice, while blood levels rose from 15 nM to 1,719 nM, indicating successful sequestration of the drug in the bloodstream.

Psypost

The work was led by Kim D. Janda, professor of chemistry and immunology at Scripps Research and director of the Worm Institute of Research and Medicine. Janda emphasizes that the vaccine is intended as a “biological safety net” to prevent fatal overdose rather than a cure for opioid addiction. He also notes that the study’s authors released the technology patent-free to encourage broader development.

Psypost

Mouse immune physiology differs from that of humans, so dosing and efficacy may change in clinical trials. The authors propose expanding the molecular design platform to other rapidly evolving biological threats and plan to refine the formulation before initiating human safety studies.

Psypost

• “I think the value of this study is quite far reaching in that synthetic opioids are here to stay, heroin is basically dead,” — Kim D. Janda, professor of chemistry and immunology, Scripps Research

Psypost

• “The bottom line is the drug cartels/clandestine laboratories making these synthetics are always trying to skirt DEA surveillance by creating new analogues of fentanyl,” — Kim D. Janda

Psypost

• “I think it surprised the students working on it,” — Kim D. Janda

Psypost

• “Vaccines are not a catch all per se to end substance abuse disorders, rather they are more like another tool in the medicinal playbook to try and prevent overdose/substance use disorders with these opioids,” — Kim D. Janda

Psypost

• “I put this work out there patent free to let anyone who has an interest in trying to curb addiction to have at it,” — Kim D. Janda

Psypost